Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers
  • Home
  • /
  • Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers
  1. Home /
  2. Archives /
  3. Vol. 13 No. 3 (2023) /
  4. Articles

Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers

Authors

  • Karolina Makowska Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0001-5467-3137
  • Kinga Panuciak Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0001-9014-5171
  • Angelika Mastalerczyk Student Scientific Society ISOMERS, Department of Medicinal Chemistry, Medical University of Lublin, Chodźki Street 4A, 20-093 Lublin, Poland https://orcid.org/0000-0002-7576-2152
  • Emilia Nowicka Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0002-2743-1551
  • Michał Obel Student Scientific Association at the Department of Endocrinology, Medical University of Lublin, Chodźki Street 19, 20-093 Lublin, Poland https://orcid.org/0000-0003-1237-8732
  • Kamila Czyżak Student Scientific Association at the Department of Endocrinology, Medical University of Lublin, Chodźki Street 19, 20-093 Lublin, Poland https://orcid.org/0000-0003-1237-8732
  • Jan Lejman Student Scientific Association at the Department of Endocrinology, Medical University of Lublin, Chodźki Street 19, 20-093 Lublin, Poland https://orcid.org/0000-0002-8065-2839
  • Natalia Trąbka Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0001-8204-4741
  • Klaudia Jedlina Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0002-2363-2620
  • Katarzyna Pacek Medical University of Lublin, A. Racławickie 1, 20-059 Lublin, Poland https://orcid.org/0000-0001-6947-558X

DOI:

https://doi.org/10.12775/JEHS.2023.13.03.019

Keywords

CAR-T, Immunotherapy, mechanisms, strategies, treatment

Abstract

Introduction and purpose:

Chimeric antigen receptor‐T (CAR‐T) cells have achieved inspiring outcomes in the treatment for lymphoid malignancies, especially diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL), providing alternative therapeutic options for patients who failed to respond to conventional treatments. CAR-T are based on the patient's T lymphocytes, which through genetic modification, gain new abilities to detect and fight cancer cells. Although the percentage of complete remissions after standard treatment of B-cell malignancies is quite high, methods that could have an even better result regarding patient survival by reducing the side effects of treatment are still being sought to improve the quality of patients' lives. CAR-T is a culmination of many years of research in the dynamically developing area of immunotherapy as a revolutionary therapy of hematological cancers treatments.


State of knowledge:

In order to explore the topic, analysis included research available in the PubMed database. The research focused on the possibility of using CAR-T cell therapy in selected hematological cancers.


Conclusion:

CAR-T is one of the most advanced and personalized methods of immunotherapy. Despite the side effects of this method, there is still scope for improvement. Our overview summarizes all the issues that have been overcome in designing this therapy, as well as highlighting all the challenges that still need to be addressed.

References

Carroll MC. Complement and humoral immunity. Vaccine. 2008 Dec 30;26 Suppl 8(0 8):I28-33. doi: 10.1016/j.vaccine.2008.11.022. PMID: 19388161; PMCID: PMC4018718.

Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010 Jan;20(1):34-50. doi: 10.1038/cr.2009.139. Epub 2009 Dec 15. PMID: 20010915.

LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008 Sep 1;112(5):1570-80. doi: 10.1182/blood-2008-02-078071. PMID: 18725575; PMCID: PMC2518873.

Fabbri M, Smart C, Pardi R. T lymphocytes. Int J Biochem Cell Biol. 2003 Jul;35(7):1004-8. doi: 10.1016/s1357-2725(03)00037-2. PMID: 12672468.

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May;94(S1):S3-S9. doi: 10.1002/ajh.25418. Epub 2019 Feb 18. PMID: 30680780.

Marks P. The FDA's Regulatory Framework for Chimeric Antigen Receptor-T Cell Therapies. Clin Transl Sci. 2019 Sep;12(5):428-430. doi: 10.1111/cts.12666. Epub 2019 Jul 22. PMID: 31328862; PMCID: PMC6743015.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866. PMID: 29385370; PMCID: PMC5996391.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. PMID: 30501490.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. PMID: 30518502; PMCID: PMC6733402.

Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2020 Sep;26(9):1581-1588. doi: 10.1016/j.bbmt.2020.06.008. Epub 2020 Jun 17. PMID: 32561336.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1. PMID: 32888407.

Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017 Jun 24;5:22. doi: 10.1186/s40364-017-0102-y. PMID: 28652918; PMCID: PMC5482931.

Pang Y, Hou X, Yang C, Liu Y, Jiang G. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Mol Cancer. 2018 May 16;17(1):91. doi: 10.1186/s12943-018-0840-y. PMID: 29769134; PMCID: PMC5956614.

Sermer D, Brentjens R. CAR T-cell therapy: Full speed ahead. Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591. PMID: 31187533.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25. PMID: 27111235; PMCID: PMC4887159.

Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995 Aug;18(5-6):385-97. doi: 10.3109/10428199509059636. PMID: 8528044.

Riet T, Holzinger A, Dörrie J, Schaft N, Schuler G, Abken H. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol. 2013;969:187-201. doi: 10.1007/978-1-62703-260-5_12. PMID: 23296935.

Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol. 2020 Sep;86(9):1678-1689. doi: 10.1111/bcp.14281. Epub 2020 Mar 24. PMID: 32175617; PMCID: PMC7444796.

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7. PMID: 33824268; PMCID: PMC8024391.

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29. PMID: 26516065; PMCID: PMC4670800.

Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016 Sep 28;14:357-362. doi: 10.1016/j.csbj.2016.09.003. PMID: 27761200; PMCID: PMC5061074.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226. PMID: 24553386; PMCID: PMC4684949.

Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017 Sep;9(9):1183-1197. doi: 10.15252/emmm.201607485. PMID: 28765140; PMCID: PMC5582407.

Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, Zhu H, Mao Y, Xu Z, Li J. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review. Ann Hematol. 2018 Aug;97(8):1327-1335. doi: 10.1007/s00277-018-3368-8. Epub 2018 May 15. PMID: 29766234.

Downloads

  • PDF

Published

2023-01-26

How to Cite

1.
MAKOWSKA, Karolina, PANUCIAK, Kinga, MASTALERCZYK, Angelika, NOWICKA, Emilia, OBEL, Michał, CZYŻAK, Kamila, LEJMAN, Jan, TRĄBKA, Natalia, JEDLINA, Klaudia and PACEK, Katarzyna. Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers. Journal of Education, Health and Sport. Online. 26 January 2023. Vol. 13, no. 3, pp. 134-139. [Accessed 28 June 2025]. DOI 10.12775/JEHS.2023.13.03.019.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 13 No. 3 (2023)

Section

Articles

License

Copyright (c) 2023 Karolina Makowska, Kinga Panuciak, Angelika Mastalerczyk, Emilia Nowicka, Michał Obel, Kamila Czyżak, Jan Lejman, Natalia Trąbka, Klaudia Jedlina, Katarzyna Pacek

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 436
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

CAR-T, Immunotherapy, mechanisms, strategies, treatment
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop